홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /반응

1-(3,5-Dicyclopropylpyridin-2-yl)piperazine hydrochloride → [4-(3,5-Dicyclopropylpyridin-2-yl)piperazin-1-yl][4-(1,1-dioxo-1lambda6-isothiazolidin-2-yl)-2-methanesulfonylphenyl]methanone

HRID 2411536
인쇄

반응식

HRID 2411536 반응식
[O:1]=[S:2]1(=[O:20])[CH2:6][CH2:5][CH2:4][N:3]1[C:7]1[CH:15]=[CH:14][C:10]([C:11]([OH:13])=O)=[C:9]([S:16]([CH3:19])(=[O:18])=[O:17])[CH:8]=1.Cl.[CH:22]1([C:25]2[C:26]([N:34]3[CH2:39][CH2:38][NH:37][CH2:36][CH2:35]3)=[N:27][CH:28]=[C:29]([CH:31]3[CH2:33][CH2:32]3)[CH:30]=2)[CH2:24][CH2:23]1>>[CH:22]1([C:25]2[C:26]([N:34]3[CH2:35][CH2:36][N:37]([C:11]([C:10]4[CH:14]=[CH:15][C:7]([N:3]5[CH2:4][CH2:5][CH2:6][S:2]5(=[O:1])=[O:20])=[CH:8][C:9]=4[S:16]([CH3:19])(=[O:18])=[O:17])=[O:13])[CH2:38][CH2:39]3)=[N:27][CH:28]=[C:29]([CH:31]3[CH2:33][CH2:32]3)[CH:30]=2)[CH2:23][CH2:24]1
참가 물질실험 절차후처리출처 및 근거반응 노트

참가 물질

3

반응물 2

HCID 673810941-(3,5-Dicyclopropylpyridin-2-yl)piperazine hydrochlorideHCID 712521084-(1,1-Dioxo-1lambda6-isothiazolidin-2-yl)-2-methanesulfonylbenzoic acid

생성물 1

HCID 71252411[4-(3,5-Dicyclopropylpyridin-2-yl)piperazin-1-yl][4-(1,1-dioxo-1lambda6-isothiazolidin-2-yl)-2-methanesulfonylphenyl]methanone수율 78.5%

실험 절차

Using 4-(1,1-dioxo-1λ6-isothiazolidin-2-yl)-2-methanesulfonylbenzoic acid (319 mg) described in Preparation Example 22 and 1-(3,5-dicyclopropylpyridin-2-yl)piperazine hydrochloride (280 mg) described in Preparation Example 87 and by the reaction and treatment in the same manner as in Example 86, the title compound (427 mg) was obtained.

후처리

  1. customdescribed in Preparation Example 87 and by the reaction and treatment in the same manner as in Example 86

출처 및 근거

ORD 기록
ord-696f05c09b274ffd90488cb46a1f666a
출처 데이터셋
uspto-grants-2014_08
DOI
10.6084/m9.figshare.5104873.v1
특허 번호
US08816079B2

반응 노트

이 페이지에서참가 물질실험 절차후처리출처 및 근거반응 노트